News >

Expert Discusses Latest Developments in MPNs

Jonathan Alicea and Gina Columbus
Published: Wednesday, Jul 26, 2017

Dr. Rami S. Komrokji

Rami S. Komrokji, MD
Diagnostic and treatment advances have advanced the field of myeloproliferative neoplasms (MPNs) over the past several years, says Rami Komrokji, MD, who discussed MPNs at the 2017 OncLive® State of the Science Summit™.

Komrokji, vice chair of malignant hematology and section head for leukemia and MDS at Moffitt Cancer Center, shared his insight on the various types of MPNs, how these diseases can be diagnosed and managed, and the next steps needed to improve patient outcomes.

OncLive: Please provide an overview of your talk on MPNs.

Komrokji: The field had evolved in the last few years with all of the discoveries in biology, the integration of somatic gene mutations in diagnosis, and risk certification for those patients. I gave a bit of an overview of the biology of the disease, the difference between the disease initiating, and mutations versus the phenotype driving mutations. I went into a little bit more detail about those mutations like JAK2 V617F, the calreticulan mutation, or MPL mutations— what we call phenotype-driving mutations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication